GB0130778D0 - Novel compounds - Google Patents

Novel compounds

Info

Publication number
GB0130778D0
GB0130778D0 GBGB0130778.4A GB0130778A GB0130778D0 GB 0130778 D0 GB0130778 D0 GB 0130778D0 GB 0130778 A GB0130778 A GB 0130778A GB 0130778 D0 GB0130778 D0 GB 0130778D0
Authority
GB
United Kingdom
Prior art keywords
chromophore
protein
conjugation
conjugating
bound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0130778.4A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Catalyst Biomedica Ltd
Original Assignee
Catalyst Biomedica Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Catalyst Biomedica Ltd filed Critical Catalyst Biomedica Ltd
Priority to GBGB0130778.4A priority Critical patent/GB0130778D0/en
Publication of GB0130778D0 publication Critical patent/GB0130778D0/en
Priority to AU2002353209A priority patent/AU2002353209A1/en
Priority to PCT/GB2002/005867 priority patent/WO2003055887A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

The invention provides a porphyrin, chlorin or bacteriochlorin chromophore, which chromophore comprises one conjugating meso substituent which comprises a conjugating group Z for covalently conjugating said chromophore to a protein so as to enable delivery of the chromophore to a selected biological target in vitro or in vivo, and one, two or three hydrophilic meso substituents, wherein the hydrophilicity of the chromophore is such that either on carrying out conjugation of said chromophore to said protein by way of incubating said chromophore and said protein for one hour under standard protein conjugation conditions in 10% DMSO/water buffered to pH 9, the percentage of non-covalently bound chromophore out of total protein-bound chromophore is 5% or less; or, where said protein is bovine serum albumin, on carrying out conjugation of said chromophore to said protein by way of incubating said chromophore and said protein for one hour under standard protein conjugation conditions in 10% DMSO/water buffered to pH 9, the percentage of non-covalently bound chromophore out of total protein-bound chromophore is 20% or less. The invention further provides methods for the synthesis of such chromophores, and methods for the use of such chromophores in therapy and in analysis.
GBGB0130778.4A 2001-12-21 2001-12-21 Novel compounds Ceased GB0130778D0 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
GBGB0130778.4A GB0130778D0 (en) 2001-12-21 2001-12-21 Novel compounds
AU2002353209A AU2002353209A1 (en) 2001-12-21 2002-12-20 Conjugated porphyrin, chlorin or bacteriochlorin chromophore
PCT/GB2002/005867 WO2003055887A1 (en) 2001-12-21 2002-12-20 Conjugated porphyrin, chlorin or bacteriochlorin chromophore

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0130778.4A GB0130778D0 (en) 2001-12-21 2001-12-21 Novel compounds

Publications (1)

Publication Number Publication Date
GB0130778D0 true GB0130778D0 (en) 2002-02-06

Family

ID=9928268

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0130778.4A Ceased GB0130778D0 (en) 2001-12-21 2001-12-21 Novel compounds

Country Status (3)

Country Link
AU (1) AU2002353209A1 (en)
GB (1) GB0130778D0 (en)
WO (1) WO2003055887A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2602204T3 (en) * 2004-06-07 2017-02-20 Yeda Research And Development Co., Ltd. Cationic bacteriochlorophyll derivatives and uses thereof
WO2006009786A2 (en) * 2004-06-18 2006-01-26 Elmaleh David R Intravascular imaging device and uses thereof
US20060223750A1 (en) * 2005-04-01 2006-10-05 Allergan, Inc. Agents and methods for enhancing photodynamic therapy
EP3459955B1 (en) * 2008-09-18 2022-11-02 biolitec Unternehmensberatungs II AG Novel method and application of unsymmetrically meso-substituted porphyrins and chlorins for pdt
CZ306495B6 (en) * 2014-09-16 2017-02-15 Vysoká škola chemicko- technologická v Praze 5,15-Bis-pentafluorphenylporphyrin substituted in positions 10 and 20 with perbenzylated sucrose molecules as a substrate of matrix assisted supramolecular chirality amplification and the method of its preparation
CN109651383B (en) * 2019-01-25 2021-11-16 华东理工大学 Compounds for photosensitizers and uses thereof
US20220241765A1 (en) * 2019-05-24 2022-08-04 Glytech, Inc. Novel artificial protein catalyst

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5283255A (en) * 1987-01-20 1994-02-01 The University Of British Columbia Wavelength-specific cytotoxic agents
US5002962A (en) * 1988-07-20 1991-03-26 Health Research, Inc. Photosensitizing agents
JP2004501923A (en) * 2000-06-26 2004-01-22 カタリスト　　バイオメディカ　リミテッド Chromophore improvement and chromophore improvement

Also Published As

Publication number Publication date
WO2003055887A1 (en) 2003-07-10
AU2002353209A1 (en) 2003-07-15

Similar Documents

Publication Publication Date Title
Quinn et al. Carnosine: its properties, functions and potential therapeutic applications
Oi et al. Fluorescent phycobiliprotein conjugates for analyses of cells and molecules.
Kikuchi et al. Zinc sensing for cellular application
US5055556A (en) Fluorescent conjugates for analysis of molecules and cells
US4859582A (en) Fluorescent conjugates for analysis of molecules and cells
Sadzuka et al. The effects of theanine, as a novel biochemical modulator, on the antitumor activity of adriamycin
Blinova et al. Mitochondrial NADH fluorescence is enhanced by complex I binding
WO2005084390A3 (en) Partially loaded antibodies and methods of their conjugation
EP2281568A3 (en) Uses of soluble CTLA4 mutant molecules
BRPI9912227B8 (en) method for early in vitro diagnosis of carcinomas and their early stages and kit for carrying out the method.
BR0212809A (en) Gdf-8 Antibody Inhibitors and Uses
WO2006052924A3 (en) Methods and compositions for protein-hydroxy apatite complexes and their application in testing and modulating immunological system including a novel in vitro test for the detection of antibodies against calcium binding protein-hydroxy apatite complexes
EP0076695A1 (en) Fluorescent conjugates for analysis of molecules and cells
AU2002365365A1 (en) Metal complex compounds
You et al. Rational modulation of the luminescence of upconversion nanomaterials with phycocyanin for the sensing and imaging of myeloperoxidase during an inflammatory process
GB0130778D0 (en) Novel compounds
NZ202563A (en) Anticancer drug:chain a of ricin conjugated to monoclonal antibody(or fragment)of anti-leukemic t-cell specificity
Hanessian et al. Synthesis of chemically functionalized superparamagnetic nanoparticles as delivery vectors for chemotherapeutic drugs
Komath et al. Fluorescence and absorption spectroscopic studies on the interaction of porphyrins with snake gourd (Trichosanthes anguina) seed lectin
Yang et al. Green fluorescent probe for imaging His6-tagged proteins inside living cells
Qin et al. Targeted mitochondrial fluorescence imaging-guided tumor Antimetabolic therapy with the imprinted polymer nanomedicine capable of specifically recognizing Dihydrofolate reductase
CA2366514A1 (en) Diagnostic and therapeutic use of antibodies against the urokinase receptor
Kang et al. Theranostic Polyaminocarboxylate–Cyanine–Transferrin Conjugate for Anticancer Therapy and Near‐Infrared Optical Imaging
Taraboletti et al. Endothelial cell migration and invasiveness are induced by a soluble factor produced by murine endothelioma cells transformed by polyoma virus middle T oncogene
Szczygieł et al. Central metal determines pharmacokinetics of chlorophyll-derived xenobiotics

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)